MCA205 Syngeneic Model Service for Sarcoma

The MCA205 Syngeneic Model Service for Sarcoma offers a chemically induced, immunocompetent fibrosarcoma system that recapitulates the tumor–immune dynamics central to soft-tissue sarcoma research. Alfa Cytology supports the full study lifecycle of this model — C57BL/6 mouse inoculation, longitudinal tumor monitoring, immune-checkpoint and combination-therapy dosing, and detailed endpoint characterization — delivering dependable preclinical data for sarcoma programs.

Overview of MCA205 Syngeneic Model for Sarcoma

MCA205 is a murine fibrosarcoma cell line originally induced in C57BL/6 mice by the carcinogen 3-methylcholanthrene, then maintained in vivo through serial subcutaneous transplantation before being adapted to in vitro culture. Classified as a weakly immunogenic tumor, MCA205 occupies a valuable middle ground in immuno-oncology: it grows progressively in syngeneic hosts, yet expresses sufficient tumor-associated antigens and moderate MHC class I levels to engage the adaptive immune system. The line is therefore one of the most widely used models for inducing tumor-reactive T lymphocytes, dissecting antigen presentation, and benchmarking adoptive cell therapies and cytokine-based interventions.

Fig 1. Verapamil inhibits MCA205 fibrosarcoma in vitro and enhances anti-PD-1 efficacy in the MCA-205 syngeneic model: VEGF reduction, tumor growth curves, excised tumors, survival, and CD8+ T cell infiltration. (Sun, Jianwen, et al., 2024)

Following subcutaneous implantation into C57BL/6 mice, MCA205 tumors establish reliably with predictable kinetics and display notable sensitivity to immune-checkpoint blockade — responding robustly to anti-PD-1 and anti-PD-L1 antibodies and partially to standard-of-care agents such as doxorubicin — while still offering dynamic range for combination optimization. Because the host immune system remains fully functional, the model faithfully reproduces lymphoid and myeloid infiltration, CD8⁺ T-cell-mediated tumor control, and immunosuppressive microenvironment features (including myeloid-derived suppressor cells and M2 macrophages) that are difficult to study in xenograft settings. Luciferase-tagged MCA205 derivatives further enable non-invasive tracking in vivo, supporting both efficacy studies and mechanism-of-action investigations.

Cell Line Information: MCA205

MCA205 (also written MCA-205 or MCA 205) is a well-established murine fibrosarcoma line whose immunological profile makes it a standard platform for sarcoma immuno-oncology research. Its principal characteristics are summarized below.

Our Services

Alfa Cytology runs the MCA205 syngeneic model within a dedicated preclinical in vivo facility, pairing standardized C57BL/6 colony operations with flexible study configurations — from straightforward single-agent efficacy arms to checkpoint-combination, rechallenge, and immune-profiling designs — so each sarcoma program receives data matched to its specific mechanism-of-action and decision-making needs.

Workflow of MCA205 Syngeneic Model Construction

Building a reliable MCA205 syngeneic study proceeds through a series of controlled stages designed to guarantee consistent tumor take and meaningful readouts. The workflow is outlined below:

1. Cell Line Qualification: MCA205 cells are STR-authenticated, confirmed mycoplasma-negative, and expanded at low passage to retain growth and immunogenic characteristics.
2. Mouse Acclimatization and Randomization: C57BL/6 mice (typically 6–8 weeks old) are acclimatized under specific-pathogen-free conditions and randomized to treatment groups.
3. Tumor Cell Inoculation: Single-cell suspensions (commonly 0.5–2 × 10⁶ cells in 100–200 µL) are injected subcutaneously into the flank; in vivo-luciferase variants are used where imaging is required.
4. Model Establishment Monitoring: Implant sites are palpated and, once tumors become measurable, caliper readings begin alongside body-weight and health-status recording.
5. Group Randomization and Dosing: When tumors reach the target volume (e.g., approximately 100 mm³), animals are re-randomized and dosing with vehicle, reference agents (e.g., anti-PD-1, anti-PD-L1), or test articles commences.
6. In-Life Assessment: Tumor growth and body weight are tracked on a scheduled basis; bioluminescence imaging is performed for luciferase-tagged studies to follow disease burden non-invasively in vivo.
7. Endpoint Analysis: At termination, tumors are excised and weighed, and tissues are processed for histology, flow-cytometric immune profiling, or molecular analysis as specified.
8. Reporting: Tumor-growth curves, survival analysis, and immune-endpoint data are integrated into a final study report with statistical interpretation.

Fig 2. MCA205 Syngeneic Model construction workflow.

Case Study-MCA205 Syngeneic Model Development

In a recent preclinical engagement, Alfa Cytology established the MCA205 syngeneic sarcoma model for a sponsor assessing an immunomodulatory therapeutic approach. The engagement covered model setup in C57BL/6 mice, treatment-arm allocation with reference checkpoint inhibitors, scheduled in-life monitoring of tumor burden and body weight, and terminal immune-profiling of tumor tissue — yielding an integrated dataset that informed the client’s preclinical development strategy. Case formats can be adapted to single-agent, combination, rechallenge, or biomarker-oriented designs according to program requirements.

Why Choose Alfa Cytology?

Alfa Cytology combines hands-on syngeneic model expertise with disciplined study execution, providing a smooth route from concept to decision-ready results. Researchers partner with us because of the following strengths:

• Deep working experience with MCA205 and a diverse panel of immunocompetent sarcoma models.
• Versatile study designs spanning monotherapy, checkpoint combinations, and rechallenge formats.
• Integrated immune-profiling capability, including flow cytometry and histopathology readouts.
• Rigorous quality practices covering cell authentication, randomization, and blinded assessments.
• Tailored endpoints from tumor growth and survival through to tumor-microenvironment characterization.
• Attentive project communication and dependable reporting timelines.

Contact Us

If your sarcoma program calls for a responsive, immunocompetent in vivo system, the MCA205 syngeneic model specialists at Alfa Cytology are ready to help. Reach out to us to discuss study design, timelines, and pricing, or contact us for a tailored quotation — we would be glad to support your next preclinical milestone.

For research use only. Not intended for any clinical use.